Background
==========

The invasive lobular carcinoma (ILC), known to be the second most common histologic subtype of invasive breast cancer following the invasive ductal carcinoma (IDC), constitutes 8-14% of all breast cancers in most Western reports \[[@B1]-[@B3]\]. However, in Asia it appears to be very low, accounting for only 2-4% in Korea \[[@B4]-[@B6]\] and 1-4% in Japan \[[@B7],[@B8]\].

Previous studies have demonstrated distinctive clinical and biologic characteristics for ILC as compared with IDC. For example, it is more likely to occur in older patients, be larger in size, be estrogen receptor (ER) and progesterone receptor (PgR) positive and have low to absent human epidermal growth factor receptor-2 (HER2) expression \[[@B9],[@B10]\]. Traditionally, both ILC and IDC subtypes have received the same treatment, depending on their clinicopathological characteristics, and the prognosis is reported to be similar \[[@B10],[@B11]\].

Recently, classification of breast cancers by gene expression profiling into particular subtypes has become established \[[@B12]\]. However, in clinical practice, the combination of expression of hormone receptors and HER2 by immunohistochemistry (IHC) is more commonly used to define breast cancers into the luminal A (ER^+^or PgR^+^, HER2^-^), luminal B (ER^+^or PgR^+^, HER2^+^), HER2-overexpressing (ER^-^and PgR^-^, HER2^+^), and triple-negative (TNBC: ER^-^, PgR^-^, HER2^-^) subtypes, which demonstrate major differences in clinical outcomes, with the luminal A subtype showing the best prognosis \[[@B13],[@B14]\]. The relative distributions of these four immunohistochemically defined subtypes in the lobular lesions have yet to be established in detail.

The purpose of the current study was to analyze the characteristics of an ILC series and compare the clinical and prognostic parameters with those of general IDC and of the luminal A subtype of IDC (LA-IDC).

Methods
=======

Patients
--------

All patients were treated at the National Cancer Center, Korea during the years from 2001 to 2008. A total of 83 consecutive cases diagnosed with pure ILC, including two cases with synchronous bilateral ILC, were enrolled in the study All ILC cases were classic subtype except for one case which was pleomorphic type. This particular case was triple negative by IHC. To compare clinicopathological characteristics and prognoses, 2,833 consecutive patients diagnosed with IDC during the same period were also selected.

Clinicopathological evaluation
------------------------------

We retrospectively evaluated conventional clinicopathological factors, including treatment modalities (type of operation, use of chemotherapy, hormone therapy, anti-HER2 therapy and radiotherapy) and the IHC results for five biological factors (ER \[SP1\], Ventana; PgR \[1E2\], Ventana; HER2 \[polyclonal\], DAKO; p53 \[Bp53-11\], Ventana; and Ki-67 \[MIB-1\], DAKO) using paraffin-embedded tissues according to the reported recommendations for tumor marker prognostic studies (REMARK) \[[@B15]\]. The pathological tumor stage was assessed according to the criteria described in the 6th edition of the American Joint Committee on Cancer (AJCC) staging manual \[[@B16]\]. The tumor grade was determined according to the Scarff-Bloom-Richardson classification modified by Elston and Ellis \[[@B17]\].

A cut-off value of 10% of positively stained nuclei was used to define ER and PgR positivity; HER2 was scored as 0-3+ by a pathologist (Y. Kwon) according to the method recommended for the Dako Hercep Test. Cases with IHC scores of 3+ or 2+ with gene amplification by fluorescence in situ hybridization (FISH) were considered positive for HER2. Cells with positive staining for Ki-67 and p53 were counted and expressed as a percentage. For p53, we scored the lesions as 0-3+ (0, negative; 1+, ≤25%; 2+, 25-50%; 3+, \>50%). For the prognosis comparison, low expression was defined as Ki-67 \< 20% and p53 ≤ 25% (median values for all evaluated tumors).

For the subgroup analysis, the definition of Luminal A was as follows: positive ER or PgR by IHC, negative HER2 represented by an IHC score of 0 or 1+, or 2+ if not amplified by FISH. The HER2 cases of an IHC score of 2+ but no FISH results were counted as unknowns. The definitions of the other subtypes were as follows: Luminal B, ER or PgR positive and HER2 positive; HER2 overexpressing, low ER and PgR scores but HER2 positive; TNBC, low ER and PgR scores and HER2-negative.

Treatment, including surgery, adjuvant chemo, endocrine or anti-HER2 therapy, and radiotherapy, was applied equally to patients with ILC and IDC, dependent on the clinicopathological characteristics.

Statistical analysis
--------------------

The primary endpoints of this study were disease-free survival (DFS) and overall survival (OS). The DFS period was defined as the interval from the date of diagnosis to the date of the first observation of disease recurrence, either loco-regional recurrence or distant metastasis, or the last follow-up date without any evidence of recurrence. Overall survival was calculated from the date of primary breast cancer diagnosis to the date of death or last follow-up.

To compare the clinicopathological characteristics between pairs of groups, we used the Student\'s t-test and the chi-square test. The DFS and OS rates were calculated using the Kaplan-Meier method, and the groups were compared using the log-rank test. For the multivariate analysis, Cox regression analysis was applied. Statistical analyses were performed using Stata 10.0 for Windows (Stata Corporation Station, TX, USA).

This study protocol was reviewed and approved by the Institutional Review Board of the National Cancer Center (NCCNCS-10-371), Korea, and it complied with the recommendations of the Declaration of Helsinki for biomedical research involving human subjects. The ethical review board supported that informed consent was not required for this study.

Results
=======

Patient characteristics
-----------------------

The clinicopathological characteristics of the 83 ILC patients and 2,833 IDC patients are summarized in Table [1](#T1){ref-type="table"}. The mean ages were 48.3 years and 48.2 years, respectively, with no difference in the distributions of age at diagnosis between ILC and IDC (Figure [1](#F1){ref-type="fig"}). Two patients with mixed lobular and ductal cancers were excluded from the analysis.

###### 

Clinicopathological characteristics of invasive lobular carcinoma, invasive ductal carcinoma, and luminal A subtype

  Characteristic      ILC          IDC           *P*           LA-IDC        *P*                                   
  ------------------- ------------ ------------- ------------- ------------- ------------- --------- ------ ------ ---------
  Mean age (years)    48.3 ± 8.5   48.2 ± 10.5   0.93          47.9 ± 10.2   0.71                                  
  pT                  T1           33            40.2          1730          61.2          0.001     667    61.4   0.001
                      T2           45            54.9          986           34.9                    373    34.4   
                      T3           4             4.9           89            3.1                     37     3.4    
                      T4           0             0             23            0.8                     9      0.8    
                      Unknown      1                           5                                     2             
  pN                  N0           46            56.1          1639          58.7          0.18      551    51.5   0.25
                      N1           24            29.3          763           27.3                    333    31.2   
                      N2           5             6.1           276           9.9                     128    12     
                      N3           7             8.5           116           4.2                     57     5.3    
                      Unknown      1                           39                                    19            
  M                   M0           83            100           2777          98            0.19      1064   97.8   0.17
                      M1           0             0             56            2                       24     2.2    
  Stage               I            25            30.1          1184          41.9          0.06      426    39.3   0.15
                      II           44            53            1248          44.2                    476    44     
                      III          14            16.9          337           11.9                    157    14.5   
                      IV           0             0             56            2                       24     2.2    
                      Unknown      0                           8                                     5             
  HG                  1 or 2       75            90.4          1438          54.9          \<0.001   576    57.3   \<0.001
                      3            8             9.6           1183          45.1                    429    42.7   
                      Unknown                                  212                                   83            
  ER                  Positive     75            90.4          1825          64.4          \<0.001   ·      ·      ·
                      Negative     8             9.6           1008          35.6                    ·      ·      
  PgR                 Positive     59            71.1          1420          50.1          \<0.001   ·      ·      ·
                      Negative     24            28.9          1413          49.9                    ·      ·      
  HER2                Negative     79            97.5          1586          74.6          \<0.001   ·      ·      ·
                      Positive     2             2.5           540           25.4                    ·      ·      
                      Unknown \*   2                           707                                   ·      ·      
  Subtype             Luminal A    74            91.4          1088          51.2          \<0.001   ·      ·      ·
                      Non-LA       7             8.6           1038          48.8                    ·      ·      
                      Unknown      2                           707                                   ·      ·      
  p53                 0 or 1+      74            93.7          2146          77.7          0.001     951    89.7   0.26
                      2+ or 3+     5             6.3           616           22.3                    109    10.3   
                      Unknown      4                           71                                    28            
  Ki-67                            10.3 ± 10.6   20.6 ± 19.8   \<0.001       13.5 ± 13.2   0.03                    
  Operation           BCS          57            68.7          2109          75.1          0.18      786    73     0.39
                      Mastectomy   26            31.3          698           24.9                    290    27     
                      None         0             0             26                                    3             
  Adjuvant therapy                                                                                                 
  Chemotherapy        Yes          68            81.9          2383          84.1          0.59      922    84.7   0.49
                      No           15            18.1          450           15.9                    166    15.3   
  Hormone therapy     Yes          79            95.2          2113          74.6          \<0.001   1057   97.2   0.31
                      No           4             4.8           720           25.4                    31     2.8    
  Anti-HER2 therapy   Yes^†^       1             1.2           164           5.8           0.08      ·      ·      ·
                      No           82            98.8          2669          94.2                    ·      ·      
  Radiotherapy        Yes          64            77.1          2323          82            0.25      879    80.8   0.41
                      No           19            22.9          510           18                      209    19.2   

\* Including 2+ for HER2 by immunohistochemistry without FISH.

† Thirty-seven of these patients were enrolled in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial \[[@B25]\] and 53 patients were enrolled in the Tykerb Evaluation After Chemotherapy (TEACH) trial \[[@B26]\].

BCS, breast-conserving surgery; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HG, histologic grade; M, distant metastasis at diagnosis; pT, pathological tumor stage; pN, pathological nodal stage; PgR, progesterone receptor.

![**Age distributions of invasive lobular carcinoma (ILC), invasive ductal carcinoma (IDC), and luminal A subtype of invasive ductal carcinoma (LA-IDC)**.](1471-2407-10-664-1){#F1}

Compared to the IDC group, significantly more ILC patients presented with a low histologic grade (HG) (HG1 or 2, 90.4% vs. 54.9%, *P*\< 0.001) and a large tumor size (≥T2, 59.8% vs. 38.8%, *P*= 0.001), although no difference was noted with respect to nodal involvement (43.9% vs. 41.3%, *P*= 0.18).

Significantly more tumors were positive for hormone receptors and had a negative HER2 status in the ILC group as compared to the IDC group (ER^+^, 90.4% vs. 64.4%, *P*\< 0.001; PgR^+^, 71.1% vs. 50.1%, *P*\< 0.001; HER2^-^, 97.5% vs. 74.6%, *P*\< 0.001), with a greater proportion of the luminal A subtype in the ILC group (91.4% vs. 51.2%, *P*\< 0.001). In addition, the mean Ki-67 value was lower in the ILC group compared to the IDC group (10.3 ± 10.6% vs. 20.6 ± 19.8%, *P*\< 0.001).

Because 91.4% of ILC were of the luminal A subtype, we further compared ILC to the 1,088 LA-IDC. Whereas significant differences between ILC and LA-IDC were found for size, HG and Ki-67, the rates of nodal involvement and the expression of p53 were similar (Table [1](#T1){ref-type="table"}).

The treatment modalities in the ILC group were also comparable to those used in the LA-IDC group. One of two patients with a HER2 positive tumor among the ILC group who developed disease recurrence received anti-HER2 treatment upon recurrence.

Univariate analysis of DFS and OS of ILC compared to IDC patients
-----------------------------------------------------------------

During the median follow-up of 56.4 (range 4.9-136.6) months, 365 patients experienced disease recurrence (6/83 ILC vs. 359/2833 IDC, *P*= 0.18) and 213 patients died (3/83 ILC vs. 210/2833 IDC, *P*= 0.28). One ILC patient experienced local recurrence, one contralateral breast cancer, and four distant metastasis.

Table [2](#T2){ref-type="table"} shows the results of the univariate analysis of DFS and OS of the ILC group and of all IDC patients. Significant prognostic factors for DFS were age at diagnosis; tumor size; lymph node involvement; individual ER, PgR, and HER2 statuses; p53 (0 or 1+ vs. 2+ or 3+); Ki-67 (cut-off: 20%); the type of operation (breast conserving surgery \[BCS\] vs. mastectomy); adjuvant hormone therapy; and intrinsic subtype (luminal A vs. non-luminal A). However, there was no significant difference in the 5-year DFS rate between ILC and all IDC (91.7% in ILC vs. 87.4% in IDC, *P*= 0.31).

###### 

Univariate analysis of disease-free survival (DFS) and overall survival (OS) of all patients

  Characteristic      Patients (n)                   5-yr DFS rate (%)   *P*    5-yr OS rate (%)   *P*    
  ------------------- ------------------------------ ------------------- ------ ------------------ ------ ---------
  Age                 \<35 yrs                       226                 79.3   \<0.001            86.3   \<0.001
                      ≥35 yrs                        2690                88.2                      93.1   
  pT                  T1                             1763                91.9   \<0.001            95.1   \<0.001
                      ≥T2                            1147                81                        89.2   
                      Unknown                        6                                                    
  pN                  Negative                       1685                93.8   \<0.001            95.9   \<0.001
                      Positive                       1191                81.4                      89.6   
                      Unknown                        40                                                   
  M                   0                              2860                                          93.9   \<0.001
                      1                              56                                            24.6   
  Stage               I                              1209                95.2   \<0.001            97.2   \<0.001
                      II                             1292                89.4                      94.8   
                      III                            351                 69.2                      80.4   
                      IV                             56                                            24.6   
                      Unknown                        8                                                    
  HG                  1 or 2                         1513                88.7   0.39               93     0.84
                      3                              1191                86.8                      92.7   
                      Unknown                        212                                                  
  ER                  Positive                       1900                91.1   \<0.001            95.7   \<0.001
                      Negative                       1016                80.6                      86.8   
  PgR                 Positive                       1479                92.4   \<0.001            96.6   \<0.001
                      Negative                       1437                82.7                      88.7   
  HER2                Negative                       1665                86.1   \<0.001            91.4   0.001
                      Positive                       542                 78.4                      88.3   
                      Unknown\*                      709                                                  
  Subtype             Luminal A (LA)                 1162                89.3   \<0.001            93.9   \<0.001
                      Non-LA                         1045                78.5                      87.1   
                      Unknown                        709                                                  
  Histological type   ILC                            83                  91.7   0.31               93.6   0.38
                      IDC                            2833                87.4                      92.5   
  p53                 0 or 1+                        2220                90.9   \<0.001            95.2   \<0.001
                      2+ or 3+                       621                 81.8                      87.1   
                      Unknown                        65                                                   
  Ki-67               ≤20%                           1902                90.1   \<0.001            94.4   \<0.001
                      \>20%                          700                 83.4                      89.1   
                      Unknown                        314                                                  
  Operation           BCS                            2166                89.5   \<0.001            94.6   \<0.001
                      Mastectomy                     724                 84.2                      88.6   
                      None                           27                                                   
  Adjuvant therapy                                                                                        
  Chemotherapy        Yes                            2318                87.7   0.38               92.6   0.87
                      No                             556                 86.6                      92.5   
  Hormone therapy     Yes                            2192                90.4   \<0.001            95.6   \<0.001
                      No                             724                 78.9                      83.9   
  Anti-HER2 therapy   Yes in HER2-positive ^†^       147                 80.7   0.77               93.1   0.48
                      No in HER2-positive            395                 77.4                      86.9   
                      HER2-negative or unknown ^§^   2374                                                 
  Radiotherapy        Yes                            2387                87.8   0.4                92.3   0.38
                      No                             529                 86.3                      92.9   

\* Including 2+ for HER2 by immunohistochemistry without FISH.

† Thirty-seven of these patients were enrolled in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial \[[@B25]\] and 53 patients were enrolled in the Tykerb Evaluation After Chemotherapy (TEACH) trial \[[@B26]\].

§ No anti-HER2 therapy due to negative or unknown for HER2 by immunohistochemistry without FISH.

ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HG, histologic grade; M, distant metastasis at diagnosis; pT, pathological tumor stage; pN, pathological nodal stage; PgR, progesterone receptor.

In the univariate analysis of OS, age, tumor size, nodal status, distant metastasis at diagnosis, individual ER, PgR, and HER2 statuses, p53, Ki-67, the type of operation, adjuvant hormone therapy and intrinsic subtype were prognostic factors. The 5-year OS rate was 93.6% for the ILC group and 92.5% for the IDC group (*P*= 0.38).

In this study, we classified the total 2,916 patients into ILC and four subtypes of IDC and compared the clinical outcomes. Figure [2 (a, b)](#F2){ref-type="fig"} presents the DFS and OS curves. The prognosis of ILC was similar to that of LA-IDC and was more favorable than with other subtypes of IDC; the 5-year DFS rates being 91.7% vs. 89.1% for LA-IDC, 80.7% for the luminal B subtype of IDC (LB-IDC), 78.9% for the triple-negative subtype of IDC (TN-IDC), and 75.9% for the HER2 overexpressing subtype (*P*\< 0.001). The 5-year OS rates were 93.6%, vs. 93.4%, 92.8%, 85.8%, and 83.9%, respectively (*P*\< 0.001).

![**Clinical outcomes according to subtypes**. Disease-free survival (DFS) curves (a) and overall survival (OS) curves (b) for patients with invasive lobular carcinoma (ILC) and 4 subtypes of invasive ductal carcinoma (IDC). DFS curves (c) and OS curves (d) for patients with ILC, LA and non-LA subtypes, adjusting for other prognostic factors in multivariate analysis. Abbreviations: ILC, invasive lobular carcinoma; LA-IDC, luminal A subtype of invasive ductal carcinoma; LB-IDC, luminal B subtype of invasive ductal carcinoma; TN-IDC, triple-negative subtype of invasive ductal carcinoma.](1471-2407-10-664-2){#F2}

Multivariate analysis of DFS and OS of ILC compared to IDC, LA-IDC, and non-LA-IDC
----------------------------------------------------------------------------------

Using the significant variables determined by the univariate analysis, we performed a multivariate analysis for DFS and OS (Table [3](#T3){ref-type="table"}). Patients younger than 35 years (HR 2.17. 95% CI 1.55-3.02, *P*\< 0.001), with a larger tumor size (HR 1.85, 95% CI 1.44-2.37, *P*\< 0.001), and lymph node involvement (HR 2.81, 95% CI 2.15-3.68, *P*\< 0.001) demonstrated an unfavorable prognosis (Table [3](#T3){ref-type="table"}). Non-LA-IDC (LB-IDC, TN-IDC, and HER2-overexpressing subtypes) showed a more unfavorable prognosis compared to LA-IDC (HR 1.69, 95% CI 1.23-2.33, *P*= 0.001), but the DFS rates for ILC and LA-IDC were similar (HR 0.77, 95% CI 0.31-1.90, *P*= 0.57).

###### 

Multivariate analysis of disease-free survival (DFS) and overall survival (OS)

                           DFS    OS                                             
  ------------------------ ------ ------------- --------- ------- -------------- ---------
  Age (\<35 yrs)           2.17   (1.55-3.02)   \<0.001   1.96    (1.27-3.02)    0.002
  pT (≥T2)                 1.85   (1.44-2.37)   \<0.001   1.72    (1.24-2.40)    0.001
  pN (positive)            2.81   (2.15-3.68)   \<0.001   2.61    (1.84-3.69)    \<0.001
  M (1)                    ·      ·             ·         10.75   (6.29-18.37)   \<0.001
  Subtype                                                                        
  LA-IDC                          1 (ref)                         1 (ref)        
  non LA-IDC               1.69   (1.23-2.33)   0.001     1.5     (0.97-2.33)    0.07
  ILC                      0.77   (0.31-1.90)   0.57      0.75    (0.18-3.09)    0.7
  p53 (\>25%)              1.27   (0.96-1.66)   0.09      1.64    (1.17-2.31)    0.004
  Ki-67 (≥20%)             1.06   (0.81-1.39)   0.67      1.08    (0.77-1.50)    0.67
  Operation (mastectomy)   1.15   (0.89-1.48)   0.29      1.14    (0.82-1.59)    0.44
  Hormone therapy (no)     1.19   (0.88-1.62)   0.25      1.81    (1.21-2.71)    0.004

CI, confidence interval; HG, histologic grade; HR, hazard ratio; LA, luminal A; M, distant metastasis at diagnosis; pT, pathological tumor stage; pN, pathological nodal stage

For OS, a young age (HR 1.96. 95% CI 1.27-3.02, *P*= 0.002), larger tumor size (HR 1.72, 95% CI 1.24-2.40, *P*= 0.001), lymph node involvement (HR 2.61, 95% CI 1.84-3.69, *P*\< 0.001), the presence of distant metastasis at first diagnosis (HR 10.75, 95% CI 6.29-18.37, *P*\< 0.001), p53 overexpression (HR 1.64, 95% CI 1.17-2.31, *P*= 0.004), and no hormone therapy (HR 1.81, 95% CI 1.21-2.71, *P*= 0.004) were identified as independent factors that were significantly associated with mortality (Table [3](#T3){ref-type="table"}). However, OS did not differ between ILC and LA-IDC patients (ILC; HR 0.75, 95% CI 1.18-3.09, *P*= 0.70).

Figure [2 (c, d)](#F2){ref-type="fig"} shows the DFS and OS curves adjusted for other prognostic factors for ILC and IDC subtypes. The DFS curves for ILC were similar to those for LA-IDC and were more favorable than those for non-LA-IDC (*P*= 0.03). The OS of ILC and LA-IDC was better than that of non-LA-IDC, but the difference did not reach statistical significance (*P*= 0.16).

Discussion
==========

ILC constitutes 2-4% of all breast cancer in Korea, as presented in the current study, which is much lower than the rate observed in most Western reports \[[@B1]-[@B3]\]. Although ILC occurs more often in older women in Western countries \[[@B9],[@B10]\], our series demonstrated that age distributions were the same as those for overall IDC at diagnosis. Notably, the peak age of breast cancer patients in Korea is the late 40 s, which is 10 to 20 years younger than that in Western countries \[[@B4]\].

In the present study, the tumor size of ILC was larger than that of IDC, as observed in other studies \[[@B10],[@B18],[@B19]\]. Detection may be delayed because ILC is often clinically impalpable or mammographically invisible due to a lack of desmoplasia in the stroma \[[@B20]\]. Despite the larger tumor size, the rate of lymph node involvement in ILC did not differ from that in general IDC, which may reflect the slow growth rate of ILC, and this finding is consistent with other reports \[[@B10],[@B18]\]. Due to the difficulty associated with early detection, the larger tumor size in ILC adversely affected the outcomes of patients with poor DFS in the present study. We reported that ILC had lower histologic grade than IDC. Previously, Li et al. analyzed Surveillance, Epidemiology, and End Results Program data and demonstrated that ILC showed lower tumor grade than IDC specifically in 30-49 years old patient group \[[@B21]\]. Although Rakha et al. reported that histologic grade of ILC provided a strong predictor of outcome in breast cancer patients and should be provided routinely in pathology reports, we did not find such correlation \[[@B22]\].

One of the objectives of the present study was to characterize more comprehensively the biological phenotype of ILC. As previously reported \[[@B6],[@B10]\], the majority of ILC showed ER or PgR positivity and HER2 negativity, which we defined as consistent with the LA-IDC subtype. Weigelt et al. also showed that most ILC fall into luminal A molecular subtype, although some ILC had cluster with either HER2 subtype or apocrine subtype \[[@B23]\]. Furthermore, ILC demonstrated lower p53 and Ki-67 expression compared to IDC and LA-IDC. All of these characteristics suggest that ILC likely originates from more differentiated luminal cells \[[@B24]\].

Previous studies have reported that the prognosis of ILC patients is similar to that of IDC patients \[[@B6],[@B10],[@B18]\], as confirmed in the present study. Arpino et al. analyzed 4,140 ILC patients and 45,169 not otherwise specified IDC patients and reported that the histologic type did not affect the prognosis despite the favorable biological phenotype of ILC \[[@B10]\]. However, the outcome of ILC in the present study was comparable to that of LA-IDC and significantly better than the outcomes of other, non-LA-IDC subtypes, when we further analyzed the prognosis by breast cancer subtype.

This study demonstrated a new aspect of ILC after construing the data including biologic markers other than general tumor characteristics in the consecutive breast cancer patients who received consistent therapeutic approaches at a single center. Similar clinicopathological characteristics and clinical outcomes between ILC and LA-IDC were discovered after we further compared ILC with the four subtypes. To our knowledge, this is the first report to show such similarities between ILC and LA-IDC.

Conclusions
===========

ILC has distinct clinicopathological characteristics with a larger tumor at presentation, a lower HG, ER/PgR positive and HER2 negative status, and low Ki-67 expression, as compared to overall IDC. This study shows that most ILC are luminal A breast cancer, the prognosis of ILC is similar to that of LA-IDC, and both are better than the other subtypes.
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